A study is set to explore if artificial intelligence (AI) can help doctors make better decisions when it comes to treating prostate cancer. While prostate cancer diagnosis has become safer and more ...

CLEVELAND, Ohio — When it comes to cancer, deciding on the best course of treatment can sometimes feel like a coin toss. However, doctors at University Hospitals have a new tool that helps them weigh ...

Prostate cancer is the second most common cancer in men, with over 288,000 new cases diagnosed each year. It’s also one of the most curable cancers if detected early. Now, a new imaging tool is ...

FDA-authorized AI tools have the potential to help patients with prostate cancer get clearer answers instead of waiting weeks for genomic test results. FDA-authorized artificial intelligence (AI) ...

The NHS is embarking on a trial that could cut prostate cancer diagnosis times from weeks to a single day. The initiative uses artificial intelligence to analyze MRI scans, potentially transforming ...

A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize ...

The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with ...

PANAMA CITY, Fla. (WJHG/WECP) - Hope Regional Medical Center in Panama City is now using a powerful new diagnostic tool in the fight against Prostate Cancer. Doctors at the center have always used CT ...

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds. For patients enrolled in Medicare Part D prescription drug ...

Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...